SAN DIEGO, Oct. 10, 2017 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, will webcast
its Quarterly Update Conference Call for the third quarter 2017 on
Tues., Nov. 7 at 4:30 p.m. ET/1:30 p.m.
PT. Dr. Helen Torley,
president and chief executive officer, will lead the call. On the
same date, Halozyme will release financial results for the third
quarter 2017 following the close of trading.
The call will be webcast live through the "Investors" section of
Halozyme's corporate website and a recording will be made available
following the close of the call. To access the webcast and
additional documents related to the call, please visit the
Investors page of www.halozyme.com approximately fifteen minutes
prior to the call to register, download and install any necessary
audio software. The live call may be accessed by dialing (877)
410-5657 (domestic callers) or (334) 323-7224 (international
callers) using passcode 769890. A telephone replay will be
available after the call by dialing (877) 919-4059 (domestic
callers) or (334) 323-0140 (international callers) using replay ID
number 19320711.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug PEGPH20,
applies a unique approach to targeting solid tumors, allowing
increased access of co-administered cancer drug therapies to the
tumor in animal models. PEGPH20 is currently in development for
metastatic pancreatic cancer, non-small cell lung cancer, gastric
cancer, metastatic breast cancer and has potential across
additional cancers in combination with different types of cancer
therapies. In addition to its proprietary product portfolio,
Halozyme has established value-driving partnerships with leading
pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen,
AbbVie, Lilly and Bristol-Myers
Squibb for its ENHANZE® drug delivery technology.
Halozyme is headquartered in San
Diego. For more information visit www.halozyme.com.
Contacts:
Jim
Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/halozyme-to-host-third-quarter-2017-financial-results-conference-call-300533526.html
SOURCE Halozyme Therapeutics, Inc.